SecBot SecBot
SECBOTREPLAY Home › Report › TENX

TENX · The primary news is the completion of statistical analyses from the…

TENAX THERAPEUTICS, INC. · 8-K filed Nov 5, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 5, 2026 at 07:00 ET

The primary news is the completion of statistical analyses from the failed Phase 3 LEVEL trial, yielding a predictive enrichment strategy being applied to the amended LEVEL-2 protocol, and a granted Type C meeting with the FDA. Cash runway extended through fiscal 2028.

  • Cash and cash equivalents of $113.7M as of September 30, 2026; cash runway through fiscal 2028
  • Phase 3 LEVEL trial did not meet primary endpoint; post hoc analysis identified enrichment criteria for LEVEL-2
  • LEVEL-2 enrollment temporarily paused for protocol amendment to enrich for more symptomatic patients
  • FDA granted a Type C meeting to discuss overall development of levosimendan in PH-HFpEF

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access